Mersana Therapeutics, Inc. (MRSN): Price and Financial Metrics
GET POWR RATINGS... FREE!
MRSN POWR Grades
- Quality is the dimension where MRSN ranks best; there it ranks ahead of 58.45% of US stocks.
- The strongest trend for MRSN is in Growth, which has been heading down over the past 177 days.
- MRSN's current lowest rank is in the Sentiment metric (where it is better than 7.8% of US stocks).
MRSN Stock Summary
- Of note is the ratio of MERSANA THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; merely 10.45% of US stocks have a lower such ratio.
- With a price/sales ratio of 54.23, MERSANA THERAPEUTICS INC has a higher such ratio than 96.46% of stocks in our set.
- Revenue growth over the past 12 months for MERSANA THERAPEUTICS INC comes in at 26,954.55%, a number that bests 99.87% of the US stocks we're tracking.
- Stocks that are quantitatively similar to MRSN, based on their financial statements, market capitalization, and price volatility, are LPCN, KROS, RPTX, LYRA, and BEAM.
- MRSN's SEC filings can be seen here. And to visit MERSANA THERAPEUTICS INC's official web site, go to www.mersana.com.
MRSN Valuation Summary
- MRSN's price/sales ratio is 53.6; this is 2514.63% higher than that of the median Healthcare stock.
- Over the past 68 months, MRSN's price/earnings ratio has gone up 16.2.
Below are key valuation metrics over time for MRSN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MRSN | 2023-01-20 | 53.6 | 7.1 | -3.1 | -2.4 |
| MRSN | 2023-01-19 | 48.8 | 6.4 | -2.8 | -2.1 |
| MRSN | 2023-01-18 | 47.3 | 6.2 | -2.7 | -2.0 |
| MRSN | 2023-01-17 | 48.2 | 6.4 | -2.8 | -2.1 |
| MRSN | 2023-01-13 | 50.8 | 6.7 | -2.9 | -2.2 |
| MRSN | 2023-01-12 | 53.2 | 7.0 | -3.0 | -2.4 |
MRSN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MRSN has a Quality Grade of D, ranking ahead of 22.8% of graded US stocks.
- MRSN's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
- ARNA, EYEG, and AGTC are the stocks whose asset turnover ratios are most correlated with MRSN.
The table below shows MRSN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.000 | 1 | -19.265 |
| 2021-03-31 | 0.003 | 1 | -11.244 |
| 2020-12-31 | 0.003 | 1 | -4.878 |
| 2020-09-30 | 0.004 | 1 | -3.132 |
| 2020-06-30 | 0.011 | 1 | -2.130 |
| 2020-03-31 | 0.009 | 1 | -2.198 |
MRSN Price Target
For more insight on analysts targets of MRSN, see our MRSN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $26.67 | Average Broker Recommendation | 1.29 (Strong Buy) |
MRSN Stock Price Chart Interactive Chart >
MRSN Price/Volume Stats
| Current price | $6.58 | 52-week high | $8.34 |
| Prev. close | $6.50 | 52-week low | $2.68 |
| Day low | $6.49 | Volume | 655,332 |
| Day high | $6.74 | Avg. volume | 1,091,272 |
| 50-day MA | $6.27 | Dividend yield | N/A |
| 200-day MA | $5.79 | Market Cap | 656.51M |
Mersana Therapeutics, Inc. (MRSN) Company Bio
Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patients’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.
Latest MRSN News From Around the Web
Below are the latest news stories about MERSANA THERAPEUTICS INC that investors may wish to consider to help them evaluate MRSN as an investment opportunity.
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing TumorsFirst Immunosynthen ADC product candidate enters the clinicCAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the initiation of patient dosing in its Phase 1 clinical trial of XMT-2056, the company’s lead Immunosynthen product candidate. XMT-2056 is a system |
With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana TherapeuticsCiti initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating and a price target of $12. The analyst says the topline registrational data (expected in mid-2023) from the UPLIFT Ph2 study evaluating upifitamab rilsodotin (UpRi; NaPi2b ADC) in platinum-resistant ovarian cancer (PROC) will be a catalyst of significant debate. Citi analyst says that while readout will be binary, investors are underappreciating UPLIFT’s probability of success in NaPi2b-high patients, given the |
Zai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock?Zai Lab Limited Unsponsored ADR (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on January 3, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 25,575 shares of its common stock a |
Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected MilestonesReport top-line data from UPLIFT registrational trial in mid-2023, submit potential BLA around year end 2023, and prepare for potential U.S. commercial launch in 2024Advance Phase 3 UP-NEXT and Phase 1 UPGRADE-A trials in platinum-sensitive ovarian cancerAdvance XMT-1660 and XMT-2056 Phase 1 trials Continue pursuing collaborations to maximize platform and pipeline potentialCapital resources expected to support operating plan commitments into the second half of 2024 CAMBRIDGE, Mass., Jan. 06, 202 |
MRSN Price Returns
| 1-mo | 12.29% |
| 3-mo | -11.56% |
| 6-mo | 32.93% |
| 1-year | 37.95% |
| 3-year | -2.52% |
| 5-year | -54.21% |
| YTD | 12.29% |
| 2022 | -5.79% |
| 2021 | -76.63% |
| 2020 | 364.40% |
| 2019 | 40.44% |
| 2018 | -75.17% |
Continue Researching MRSN
Want to do more research on Mersana Therapeutics Inc's stock and its price? Try the links below:Mersana Therapeutics Inc (MRSN) Stock Price | Nasdaq
Mersana Therapeutics Inc (MRSN) Stock Quote, History and News - Yahoo Finance
Mersana Therapeutics Inc (MRSN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...